Nektar Therapeutics buy tamam
Start price
29.06.18
/
50%
€43.49
Target price
04.11.21
€23.00
Performance (%)
-66.81%
End price
05.11.21
€14.44
Summary
This prediction ended on 05.11.21 with a price of €14.44. Massive losses of -66.81% were the result for the BUY prediction by tamam. tamam has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Nektar Therapeutics | -1.229% | -1.229% | 139.636% | -89.171% |
| iShares Core DAX® | 0.051% | 5.593% | 14.403% | 19.767% |
| iShares Nasdaq 100 | 1.808% | 7.445% | 34.917% | 57.237% |
| iShares Nikkei 225® | 2.181% | 2.815% | 11.116% | 8.873% |
| iShares S&P 500 | 1.040% | 4.975% | 27.631% | 48.786% |
Comments by tamam for this prediction
In the thread Nektar Therapeutics diskutieren
tamam stimmt der Outperform-Einschätzung der institutionellen Analysten zu
tamam stimmt am 29.06.2018 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 94.9$ zu.
Kursziel geändert auf 38,0
Kursziel geändert auf 23,0
In the thread Trading Nektar Therapeutics
Die von tamam gewählte maximale Laufzeit wurde überschritten